Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 7,017

Document Document Title
WO/2021/062559A1
This disclosure relates to carmabinoid derivatives of Formula (1) wherein R4 or R7 is a carboxamide group, pharmaceutical compositions comprising these compounds and methods of using the carmabinoid derivatives. These compounds are poten...  
WO/2021/058754A1
The invention provides a composition of matter which: • (i) consists of at least 90 % by weight of an atropisomer (2A) and 0-10 % by weight of an atropisomer of formula (2B); or • (ii) consists of at least 90 % by weight of an atropi...  
WO/2021/062199A1
Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.  
WO/2021/055849A1
The application relates to lipids of Formula (A-1) and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include such a lipid as well as additional lipids such as phospholipids, structural lipids, and...  
WO/2021/050672A1
Described herein are compounds that are kinase inhibitors. The disclosed compounds have improved properties that lead to specific targeting of kinases without inhibiting the activity of related enzymes including, making them useful for t...  
WO/2021/047627A1
A compound as shown in formula (II) and a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the compound as an active ingredient, and use thereof in the preparation of medicaments for protein degradation.  
WO/2021/050555A1
The present invention relates to compositions and methods for the treatment of disorders that lead to accumulation of oxalate, such as primary hyperoxaluria 1.  
WO/2021/038501A1
The present invention discloses an isoxazoline compound of formula (I), wherein, R1, R2a, R2b, R2c, A, T and Z are as defined in the detailed description. The present invention further discloses methods for preparation of compounds of fo...  
WO/2021/037156A1
Disclosed are a crystal of a carcinogenic fused kinase inhibitor and a preparation method therefor; also disclosed are applications of the crystal in preparing a medicament for treating tumor-related diseases.  
WO/2021/033633A1
Provided is an organic nanoparticle production method that includes a step in which a mixture including beads having an average particle size of at least 0.15 mm and no more than a value (mm) calculated by the formula 1.07 - 0.11 × (out...  
WO/2021/028810A1
The present invention relates to certain compounds, their use in therapy, as well as to pharmaceutical compositions including said compounds. Specifically, the invention relates to certain compounds and pharmaceutical compositions includ...  
WO/2021/026179A1
The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositio...  
WO/2021/018833A1
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4x, R4y, k and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for c...  
WO/2021/007661A1
The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such...  
WO/2021/008485A1
Provided are isoxazoline derivatives and uses thereof in agriculture; in particular, provided a compound having formula (I), a stereoisomer, an N-oxide or a salt thereof, preparation methods thereof, and compositions containng these comp...  
WO/2021/010492A1
The present invention provides KDM5 inhibitor. The compound disclosed herein represented by the general formula (Z): wherein all symbols have the same meanings as the definitions described in the specification; or a salt thereof is usefu...  
WO/2021/000867A1
Disclosed are an isoxazoline compound and an application thereof. The structure of the compound is as shown in general formula (I). The definitions of substituents in the formula are described in the description. The description also dis...  
WO/2021/000865A1
An isoxazoline compound, a preparation method therefor and an application thereof. The compound has a structured as represented by general formula I. Also provided is use of the compound represented by general formula I as an insecticide...  
WO/2021/000684A1
Disclosed are dihydroisoxazole compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, E, and R 1 are as defined herein. Also disclosed are compositions which comprise at least one of these dihydroisoxazole com...  
WO/2021/000297A1
Disclosed herein relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, E, and R 1 are as defined herein. Disclosed herein also relates to compositions which comprise at least one dihydroisoxazole c...  
WO/2020/262648A1
The present invention provides a compound that has an excellent pest-controlling effect and that is represented by formula (I) [in the formula, L represents an oxygen atom or CH2, E represents a C2-C10 chain hydrocarbon group or the like...  
WO/2020/254558A1
The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the ClC...  
WO/2020/254492A1
The present application relates to the use of hydroxyisoxazolines and derivatives thereof as fungicides. It also relates to new hydroxyisoxazolines derivatives, their use as fungicides and compositions comprising thereof.  
WO/2020/254489A1
The present application relates to new hydroxyisoxazolines derivatives, their use as fungicides and compositions comprising thereof. Formula (I)  
WO/2020/257139A1
The present invention provides compounds of Formula (I): (I), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA recepto...  
WO/2020/254490A1
The present invention relates to new hydroxyisoxazolines derivatives, their use as fungicides and compositions comprising thereof. Formula (I)  
WO/2020/254554A1
This disclosure relates to an improved chemical process for making compounds of formula I which are CIC-1 chloride channel inhibitors using the compounds of formula II as starting material. (Formula I, II)  
WO/2020/257138A1
The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhi...  
WO/2020/254487A1
The present disclosure relates to the use of hydroxyisoxazolines and derivatives thereof as fungicides. It also relates to new hydroxyisoxazolines derivatives, their use as fungicides and compositions comprising thereof. Formula (I)  
WO/2020/252353A1
These compounds are glutamine transporter inhibitors, e.g., alanine, serine, cysteine-preferring transporter 2 (ASCT2) inhibitors. Glutamine transporter inhibitors are useful to treat a variety of diseases, disorders, or conditions inclu...  
WO/2020/251006A1
The present invention addresses the problem of providing a production method for a 4,5-dihydroisoxazole represented by formula (5), said production method being industrially desirable, economical, and environmentally friendly. The pres...  
WO/2020/249760A1
The present invention relates to novel hydroxamic acid derivatives useful as inhibitors of astacin metalloproteinases, in particular procollagen C-proteinase (PCP) enzymes, meprins, ovastacin and/or nematode astacins; more particularly h...  
WO/2020/247665A1
Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or Hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. I...  
WO/2020/243423A1
The present invention provides compounds, compositions thereof, and methods of using the same.  
WO/2020/242943A1
This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments,...  
WO/2020/240178A1
A compound, e.g. a diamine ligand, represented by the following general formula (1): (Formula (1)) wherein each * represents an asymmetric carbon atom; X represents a group selected from one of an ester (e.g. a t-butyl ester); a thioeste...  
WO/2020/240392A1
The present invention discloses a process for the preparation of Pyroxasulfone of Formula (I) or salt thereof. Particularly, the present invention discloses an improved process for the preparation of hydroxycarbonimidic dibromide compoun...  
WO/2020/233618A1
Provided in the present invention are inhibitors for programmed cell necrosis, a preparation method therefor and a use thereof. Specifically, provided in the present invention are a compound represented by formula I and a composition com...  
WO/2020/227875A1
The present invention provides a high-purity thermostable crystal form of substituted 3-isoxazolidinone compound, preparation method therefor, and application thereof. The high-purity thermostable crystal form is prepared by a particular...  
WO/2020/227168A1
The present disclosure is directed to compounds of formulas (I) - (VII), which are useful as modulators of TRABID. The compounds are further useful in the inhibition of TRABID and the treatment of diseases or disorders associated with th...  
WO/2020/208307A1
The present invention relates to crystalline form 1 of 6-(3, 5-dimethylisoxazol-4-yl)-7- methoxy-3 -methyl- 1 -(pyridin-2-ylmethyl)quinolin-2( 1 H)-one (I) and to a method of manufacture thereof Compound (I) is a BET inhibitor useful in ...  
WO/2020/200209A1
Provided are an aromatic amine compound and a use thereof in the preparation of AR and BRD4 dual inhibitors and regulators. Specifically provided is the compound shown in formula I, said compound having dual inhibitory effects on AR and ...  
WO/2020/198026A1
The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treat...  
WO/2020/198368A1
The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disor...  
WO/2020/182723A1
The invention relates to herbicidally active 3-phenylisoxazoline-5-carboxamides of s-containing cyclopentenyl carboxylic acid esters of the general formula (I) and to their agrochemically acceptable salts (formula (I)), and to the use th...  
WO/2020/172565A1
This document provides methods and materials for increasing or maintaining NMNAT2 polypeptide levels within cells. For example, compounds (e.g., organic compounds) having the ability to increase or maintain NMNAT2 polypeptide levels with...  
WO/2020/168997A1
A compound of formula (I) is provided, it can be used in agriculture, particularly used as herbicide for controlling unwanted plants.  
WO/2020/156357A1
The present invention relates to a compound having a benzo seven-membered ring structure, a preparation method therefor, and use thereof. The compound has a structure as represented by formula (I). Provided is use of the compound having ...  
WO/2020/157710A1
The present invention disclosed 4-substituted isoxazole/isoxazoline (hetero) arylamidine compounds of general formula (I), wherein R1, R2, R3, R4, R4a, R8, R9, A, B and G have the meanings as defined in description. The present invention...  
WO/2020/157069A1
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inh...  

Matches 1 - 50 out of 7,017